Haoyu Li

Changsha, 410008, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

DLD, upregulated by YY1, fuels glioblastoma multiforme progression via EphA2 phosphorylation to activate PI3K/AKT/mTOR.

DLD, upregulated by YY1, fuels glioblastoma multiforme progression via EphA2 phosphorylation to activate PI3K/AKT/mTOR.

Journal: QJM : monthly journal of the Association of Physicians

Published: September 17, 2025

Mapping the Somatic Mutation Landscape of Familial NF2-Related Schwannomatosis using Whole-Exome Sequencing.

Mapping the Somatic Mutation Landscape of Familial NF2-Related Schwannomatosis using Whole-Exome Sequencing.

Journal: International journal of medical sciences

Published: July 12, 2025

Crosstalk between lactylation and RNA modifications in tumorigenesis: mechanisms and therapeutic implications.

Crosstalk between lactylation and RNA modifications in tumorigenesis: mechanisms and therapeutic implications.

Journal: Biomarker research

Published: June 24, 2025

A mathematical model to predict "low-lying" posterior communicating artery aneurysms in neurosurgical practice.

A mathematical model to predict "low-lying" posterior communicating artery aneurysms in neurosurgical practice.

Journal: Neurosurgical review

Published: May 08, 2024

UBE2D1 promotes glioblastoma proliferation by modulating p21 ubiquitination.

UBE2D1 promotes glioblastoma proliferation by modulating p21 ubiquitination.

Journal: Molecular carcinogenesis

Published: February 27, 2024

Knockdown lncRNA CRNDE enhances temozolomide chemosensitivity by regulating autophagy in glioblastoma.

Knockdown lncRNA CRNDE enhances temozolomide chemosensitivity by regulating autophagy in glioblastoma.

Journal: Cancer cell international

Published: May 19, 2021

PDIA4 Correlates with Poor Prognosis and is a Potential Biomarker in Glioma.

PDIA4 Correlates with Poor Prognosis and is a Potential Biomarker in Glioma.

Journal: OncoTargets and therapy

Published: October 22, 2020

LCTL Is a Prognostic Biomarker and Correlates With Stromal and Immune Infiltration in Gliomas.

LCTL Is a Prognostic Biomarker and Correlates With Stromal and Immune Infiltration in Gliomas.

Journal: Frontiers in oncology

Published: July 09, 2019

Showing 1-8 of 8

Last Updated: 09/26/2026